{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-026357","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.582880+00:00","generated_at":"2026-05-17T13:57:00.132875+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Moleculin Q2 2025 cash $7.6M; R&D expense down to $3.6M; MIRACLE trial data readout expected by year-end","bullets":["Cash and equivalents $7.6M at June 30, 2025, expected to fund operations only into Q4 2025.","R&D expense $3.6M for Q2 2025, down $0.5M from $4.1M in Q2 2024 due to reduced clinical trial activity.","G&A expense flat at $2.1M; no revenue reported for the quarter.","MIRACLE Phase 2B/3 trial expanded to 4 active sites in US, EU, and Georgia; 20+ additional sites expected by end of Q3 2025.","Anticipated unblinded data readout from first 45 subjects in MIRACLE Part A before end of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-026357","json":"https://secwatch.observer/filing/0001437749-25-026357.json","markdown":"https://secwatch.observer/filing/0001437749-25-026357.md","text":"https://secwatch.observer/filing/0001437749-25-026357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925026357/0001437749-25-026357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925026357/mbrx20250811_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:57:00.132875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}